Literature DB >> 15182341

Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.

Georgios Kalambokis1, Dimitrios Stefanou, Evanthia Arkoumani, Margarita Kitsanou, Konstantinos Bourantas, Epameinondas V Tsianos.   

Abstract

A 65-yr-old man developed increasing dyspnea and fulminant respiratory failure 48 h after introduction of hydroxyurea, oral cytarabine ocfosfate (YNK01) and interferon-alpha for treatment of Philadelphia chromosome-positive chronic myelogenous leukemia. The chest radiograph showed bilateral patchy infiltrates while computed tomography revealed multiple bullas, ground glass opacities, and patchy consolidations with possible cavitation. Bronchoscopic examination was normal and microbiological tests performed on all biologic fluids were negative. The patient did not respond to multiple antibiotic treatment and corticosteroid administration and died of progressive respiratory failure 5 d after chemotherapy introduction. The postmortem lung examination was consistent with the diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182341     DOI: 10.1111/j.1600-0609.2004.00252.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

2.  Osteoblast Hypoxia-Inducible Factor-1α Pathway Activation Restrains Osteoclastogenesis via the Interleukin-33-MicroRNA-34a-Notch1 Pathway.

Authors:  Hui Kang; Kai Yang; Lianbo Xiao; Lei Guo; Changjun Guo; Yufei Yan; Jin Qi; Fei Wang; Bernhard Ryffel; Changwei Li; Lianfu Deng
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 3.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.